Login to Your Account

Alimera, pSivida Shares Sink Following FDA's Iluvien Letter

By Tom Wall

Tuesday, December 28, 2010
Shares in Atlanta-based Alimera Sciences Inc. and partner pSivida Corp., of Watertown, Mass., sank Monday in the aftermath of an FDA complete response letter asking for analyses of the safety and efficacy data through month 36 of a Phase III trial of Iluvien (fluocinolone acetonide intravitreal insert), a sustained drug delivery system for treatment of diabetic macular edema (DME).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription